Wall Street Zen upgraded shares of Avalyn Pharma (NASDAQ:AVLN – Free Report) from a sell rating to a hold rating in a research note issued to investors on Saturday,Wall Street Zen reports.
AVLN has been the topic of several other research reports. Raymond James Financial began coverage on shares of Avalyn Pharma in a research note on Friday, October 2nd. They set an “outperform” rating and a $60.00 price objective on the stock. Morgan Stanley raised their target price on shares of Avalyn Pharma from $53.00 to $57.00 and gave the stock an “overweight” rating in a research report on Thursday, August 13th. Finally, Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Avalyn Pharma in a research note on Wednesday, November 11th. Two investment analysts have rated the stock with a Strong Buy rating, three have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $59.20.
Read Our Latest Stock Report on AVLN
Avalyn Pharma Trading Down 1.7%
Avalyn Pharma (NASDAQ:AVLN – Get Free Report) last released its quarterly earnings results on Thursday, November 12th. The company reported ($0.67) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.64) by ($0.03). On average, equities research analysts forecast that Avalyn Pharma will post -3.83 earnings per share for the current fiscal year.
Insider Activity at Avalyn Pharma
In related news, insider Fmr Llc sold 53,454 shares of the stock in a transaction on Tuesday, November 10th. The stock was sold at an average price of $30.21, for a total value of $1,614,845.34. Following the transaction, the insider directly owned 2,056,081 shares of the company’s stock, valued at approximately $62,114,207.01. This trade represents a 2.53% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.
Institutional Investors Weigh In On Avalyn Pharma
A number of institutional investors have recently added to or reduced their stakes in the company. Soleus Capital Management L.P. grew its position in Avalyn Pharma by 143.2% during the third quarter. Soleus Capital Management L.P. now owns 1,019,000 shares of the company’s stock valued at $29,031,000 after acquiring an additional 600,000 shares during the period. State Street Corp raised its holdings in shares of Avalyn Pharma by 73.7% in the 3rd quarter. State Street Corp now owns 554,004 shares of the company’s stock worth $15,784,000 after purchasing an additional 235,009 shares during the period. Profund Advisors LLC purchased a new position in shares of Avalyn Pharma in the 3rd quarter worth about $668,000. China Universal Asset Management Co. Ltd. acquired a new position in shares of Avalyn Pharma in the 3rd quarter valued at about $29,000. Finally, Manchester Capital Management LLC acquired a new position in shares of Avalyn Pharma in the 3rd quarter valued at about $36,000.
Avalyn Pharma Company Profile
Avalyn Pharma is a clinical-stage biopharmaceutical company developing inhaled treatments for pulmonary fibrosis, including idiopathic pulmonary fibrosis and other progressive fibrotic lung diseases. Its approach is designed to deliver medicine directly to the lungs. The company’s pipeline includes AP01, an investigational inhaled formulation of pirfenidone, and AP02, an investigational inhaled formulation of nintedanib. Both medicines are based on drugs used in oral form for pulmonary fibrosis, but Avalyn’s inhaled candidates are being studied as potential alternatives to oral treatment.
Further Reading
- Five stocks we like better than Avalyn Pharma
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for Avalyn Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avalyn Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
